Intellia Therapeutics is trading 5.08% down at $12.04, with the decline apparently tied to broader risk-off trading and higher Treasury yields. - Stronger U.S. business-activity data pushed the 10-year Treasury yield to its highest level since 2007. - No new company-specific announcement emerged on September 23, 2026; U.S. stocks and biotechnology shares also weakened.